Ezrin tends to be overexpressed in highly metastatic sarcoma cell lines and looks like a good potential therapeutic target for sarcoma:
http://www.sarcomahelp.org/learning_center/sarcoma_metastases.html
http://clincancerres.aacrjournals.org/content/11/17/6198.full
http://jcp.bmj.com/content/64/8/689.abstract
Yet, one study from the Netherlands suggests ezrin is not discriminative in predicting outcome in synovial sarcoma: